GibneyMXueZSwinneyMBialonczykDHirschL.Reduced silent occlusions with a novel catheter infusion set (BD FlowSmart): results from two open-label comparative studies. Diabetes Technol Ther. 2016;18(3):136-143.
2.
van BonACBodeBWSert-LangeronCDeVriesJHCharpentierG.Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2011;13(6):607-614.
3.
PfütznerASachsenheimerDGrenninglohM. Using insulin infusion sets in CSII for longer than the recommended usage time leads to a high risk for adverse events: Results from a prospective randomized crossover study. J Diabetes Sci Technol. 2015 (6):1292-1298.
4.
Dumont-FillonDTahriouHConanCChappelE.Insulin micropump with embedded pressure sensors for failure detection and delivery of accurate monitoring. Micromachines. 2014;5(4):1161-1172.
5.
Sims Deltec, Inc. Occlusion detection system for an infusion pump. December9, 1997. Available at: https://www.google.com/patents/US5695473. Accessed February 28, 2017.
6.
RaskinPHolcombeJHTamborlaneWV. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. Diabetes Complications. 2001;15(6):295-300.
7.
BodeBWeinsteinRBellD. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002;25(3):439-444.
8.
HoogmaRPSchumickiD.Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res. 2006;38(6):429-433.
9.
BodeBW.Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine. Endocr Pract. 2011;17(2):271-280.
10.
EvertABBodeBWBuckinghamBA. Improving patient experience with insulin infusion sets: practical guidelines and future directions. Diabetes Educ. 2016;42(4):470-484.
11.
van BonACDragtDDeVriesJH.Significant time until catheter occlusion alerts in currently marketed insulin pumps at two basal rates. Diabetes Technol Ther. 2012;14(5):447-448.
12.
ZisserH.Quantifying the impact of a short-interval interruption of insulin-pump infusion sets on glycemic excursions. Diabetes Care. 2008;31(2):238-239.
13.
SherrJLPalau CollazoMCengizE. Safety of nighttime 2-hour suspension of basal insulin in pump-treated type 1 diabetes even in the absence of low glucose. Diabetes Care. 2014;37(3):773-779.
14.
BorotSFrancSCristanteJ. Accuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studies. J Diabetes Sci Technol. 2014;8(6):1133-1141.
15.
HerreroPCalmRVehíJ. Robust fault detection system for insulin pump therapy using continuous glucose monitoring. J Diabetes Sci Technol. 2012;6(5):1131-1141.
16.
FacchinettiADel FaveroSSparacinoGCobelliC.An online failure detection method of the glucose sensor-insulin pump system: improved overnight safety of type-1 diabetic subjects. IEEE Trans Biomed Eng. 2013;60(2):406-416.
17.
CesconMDeSalvoDJLyTT. Early detection of infusion set failure during insulin pump therapy in Type 1 diabetes. J Diabetes Sci Technol. 2016;10(6):1268-1276.
